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Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease generally associated 
with poor prognosis. Gene expression profiles indicate the existence of distinct molecular 
subgroups, and several genetic alterations have been characterized in the past years, 
including the t(1;22)(p13;q13) and the trisomy 21 associated with GATA1 mutations. 
However, the majority of patients do not present with known mutations, and the limited 
access to primary patient leukemic cells impedes the efficient development of novel 
therapeutic strategies. In this study, using a xenotransplantation approach, we have 
modeled human pediatric AMKL in immunodeficient mice. Analysis of high-throughput 
RNA sequencing identified recurrent fusion genes defining new molecular subgroups. One 
subgroup of patients presented with MLL or NUP98 fusion genes leading to up-regulation 
of the HOX A cluster genes. A novel CBFA2T3-GLIS2 fusion gene resulting from a cryptic 
inversion of chromosome 16 was identified in another subgroup of 31% of non–Down 
syndrome AMKL and strongly associated with a gene expression signature of Hedgehog 
pathway activation. These molecular data provide useful markers for the diagnosis and 
follow up of patients. Finally, we show that AMKL xenograft models constitute a relevant 
in vivo preclinical screening platform to validate the efficacy of novel therapies such as 
Aurora A kinase inhibitors.
© 2012 Thiollier et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. Engraftment of human AMKL samples into NSG recipients. (A) Immunophenotype of patient cells at diagnosis. (B) Flow cytometry analy-
sis of blood and BM samples from recipients 6 wk after injection of 106 AMKL1 patient cells. Cells were injected either i.v. or i.f. An antibody against the 
human CD45 marker was used to specifically detect human cells in BM (top), blood, and spleen from recipients. (C) FISH analysis of leukemic cells col-
lected from primary NSG recipients engrafted with AMKL1 patient cells using probes overlapping the OTT (green) and MAL (red) loci. Note the leukemic 
cells present: one normal OTT signal, one normal MAL signal, and two split signals indicative of a balanced translocation. Arrows point to fusion signals. 
(D) RT-PCR analysis of RNA from BM cells collected from primary NSG recipients engrafted with AMKL1 patient cells to detect an OTT-MAL fusion tran-
script. RNA from 6133, a cell line expressing the OTT-MAL fusion, was used as a positive control. (E) Immunophenotype of AMKL1 secondary NSG recipi-
ents 6 wk after injection with 0.5 × 106 patient cells. (F) Immunophenotype of AMKL7 patient cells from primary, secondary, and tertiary NSG recipients 6 wk 
after injection. (G) Consistent splenomegaly with nodular infiltration in AMKL7 recipients is not observed with other AMKL samples including AMKL1. 
““ is a noninjected control NSG mouse. (H) 0.5 × 106 cells from tertiary NSG recipients (AMKL1) were injected i.f. into quaternary recipients. Immuno-
phenotype of injected BM (iBM), spleen, blood, and kidney cells at end point. (I) Human CD45+ cells were purified by flow cytometry from AMKL1 and 
AMKL7 secondary NSG recipients and injected at different doses in NSG recipients. After 4 wk, BM sampling and flow cytometry were performed. Recipi-
ents presenting a percentage of human cells (hCD45+) >0.1% were considered positive. The frequency of leukemia-propagating cells and the lower and 
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Acute megakaryoblastic leukemia (AMKL) is a heteroge-
neous subtype of acute myeloid leukemia (AML) and is 
more frequent in children than in adults (Lion et al., 1992; 
Dastugue et al., 2002; Paredes-Aguilera et al., 2003). The clin-
ical features of AMKL, including rare occurrence, low blast 
counts, myelofibrosis, and the young age of patients have 
rendered difficult the molecular characterization of genetic 
alterations and establishment of models using primary patient 
cells. In adults, AMKL leukemic blasts often present a com-
plex karyotype and frequently occur upon leukemic transfor-
mation of chronic myeloproliferative syndromes, including 
polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis, which are associated with activating mutations 
in JAK2 or MPL (James et al., 2005; Pikman et al., 2006). In 
pediatric AMKL, two molecular subtypes have been charac-
terized. The first group is represented by Down syndrome 
(DS) patients and presents with acquired GATA1 mutations 
leading to the expression of a GATA1-short (GATA1s) iso-
form lacking the wild-type transactivation domain (Wechsler 
et al., 2002; Roy et al., 2009). In non-DS AMKL, one third 
of infants present with the t(1;22)(p13;q13) chromosomal 
translocation, resulting in expression of the OTT-MAL fu-
sion protein (Ma et al., 2001; Mercher et al., 2001, 2002). To 
date, only few point mutations in genes known to be in-
volved in hematopoietic malignancies have been reported. 
Among them, the relevance of mutations in members of 
pathways involved in proliferation or survival is highlighted 
by the demonstration of activating point mutations in JAK2, 
JAK3 (Jelinek et al., 2005; Mercher et al., 2006; Walters et al., 
2006), and MPL (Malinge et al., 2008) in AMKL patients 
and by the observation that mouse models of Gata-1s or Ott-
MAL expression alone do not develop full-blown malignancy 
(Li et al., 2005; Mercher et al., 2009), whereas those with 
coexpression of Ott-MAL or Gata-1s with a mutant MPLW515L 
do (Mercher et al., 2009; Malinge et al., 2012). Together, the 
genetic basis of at least 50% of non-DS AMKL remains elu-
sive. A recent study indicates that pediatric AMKL presents a 
high number of structural alterations with 9.33 copy-number 
alterations compared with 2.38 copy-number alterations on 
average for other subtypes of pediatric AML (Radtke et al., 
2009). These observations suggest that structural genomic ab-
errations represent the major genetic basis in non-DS AMKL 
pathogenesis and that additional alterations remain to be 
identified and characterized at the molecular level.
Our limited understanding of the molecular basis for non-
DS AMKL also affects the current treatment options. Indeed, 
although DS AMKL responds well to current therapies, non-
DS AMKL patients have a poor prognosis with the majority 
of patients relapsing within 1 yr (Malinge et al., 2009). 
The development of accurate models of AMKL with pri-
mary patient leukemic cells is therefore needed to aid the 
development of novel therapies. In this study, we have de-
veloped xenotransplantation models in which human AMKL 
cells expanded and recapitulated the human disease, giving the 
opportunity to perform molecular analyses and assess the effi-
cacy of a novel differentiation therapeutic strategy in vivo.
RESULTS
Xenotransplantation of AMKL primary patient cells  
models human disease
We first assessed whether xenotransplantation in immuno-
deficient mice is a suitable approach to model pediatric 
non-DS AMKL. Blast cells from the blood or BM of seven 
AMKL patients were immunophenotyped (Fig. 1 A and 
not depicted) and injected (1–2 × 106 cells/mouse) into sub-
lethally irradiated NOD.Cg-Prkdcscid Il2rgtm1Wjll/SzJ (NSG) 
mice by either i.v. or intrafemoral (i.f.) injection. Because 
of the small number of AMKL blasts, we generally used most 
of the patient sample to inject three to five recipients and re-
tained <5 × 105 cells for molecular validation. For one pa-
tient, we transplanted both diagnosis (AMKL4) and relapse 
(AMKL4R) samples. Assessment of the engraftment was per-
formed 6 wk after injection through blood and BM sampling 
followed by flow cytometry analysis for human surface mark-
ers. Six out of eight injected samples gave rise to a significant 
engraftment, and some cryopreserved samples were able to 
engraft (Table 1). Of note, the two samples that did not en-
graft either with i.v. of i.f. injections were from adult AMKL 
patients. Two representative examples of successful engraftments, 
with cells from AMKL1 (harboring an OTT-MAL fusion) 
and AMKL7 patients (lacking known molecular alteration), 
are detailed (Fig. 1). Importantly, recipients of i.v. injections 
did not harbor significant hCD45+ leukemic cells in the BM 
as opposed to recipients of i.f. injections (Fig. 1 B). Using 
fluorescent in situ hybridization (FISH) and RT-PCR on 
cells derived from AMKL1 recipient animals, we could detect 
fusion signals and an OTT-MAL fusion transcript (Fig. 1, C and D, 
respectively), confirming that engrafted cells were derived 
from the injected AMKL1 patient leukemic blasts with the 
OTT-MAL fusion. Additional flow cytometry analysis showed 
that human cells often coexpressed megakaryocytic and eryth-
roid markers as well as immature hematopoietic markers such 
as c-KIT (Fig. 1, A, B, and E). Human leukemic cells obtained 
from successfully engrafted primary recipients were flow-
sorted to obtain DNA and RNA to perform molecular anal-
yses, and remaining cells were serially transplanted into 
secondary animals (0.5 × 106 cells/recipient). The phenotype 
of the leukemic cells was stable in secondary and subsequent 
upper limits were calculated using the L-Calc software with a 95% confidence interval. (J) Histopathological analysis of BM (left: von Willebrand immuno-
histochemistry; arrow points to an immature blast showing a low staining with von Willebrand marker) and liver (right: hematoxylin and eosin staining; 
arrow points to a focal infiltration of blasts) from AMKL1 recipients (bottom) and noninjected control NSG mouse (top). (K) Histopathological analysis of 
kidney from control and AMKL1 quaternary recipients (arrow points to infiltrated blasts). Insets show a higher magnification of the same section. Bars:  
(C) 10 µm; (G) 5 mm; (K) 200 µm; (J and K [insets]) 100 µm.
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of hCD45+ cells purified by flow cytometry from second-
ary to tertiary recipients. Tertiary recipients presenting 
>0.1% of human cells in the BM at 4 wk after transplanta-
tion were considered positive for leukemia 
engraftment and propagation. The results 
indicate a frequency of leukemia-propa-
gating cells of 1 in 5,196 for AMKL1 and 
1 in 29,972 for AMKL7 (Fig. 1 I and 
not depicted).
We then performed histopathological 
analysis to confirm that although AMKL7 
primary recipients consistently presented 
striking nodular infiltration of the spleen 
(Fig. 1 G), the majority of AMKL recipi-
ents did not show massive invasion of 
the spleen or blood with leukemic blasts 
(Fig. 1, B and G; and not depicted). Recipi-
ent animals also exhibited BM engraftment 
as revealed by positive staining of immature 
transplantations (Fig. 1, E, F, and H). To further characterize 
the AMKL1 and AMKL7 samples, we investigated the frequency 
of leukemia-propagating cells by transplanting serial dilutions 
Figure 2. CNS involvement in AMKL.  
(A) Recipient from AMKL7 cells showing spinal 
cord–localized tumor indicated by an arrow.  
(B) FACS analysis of the spinal cord tumor shown in 
A indicates that it is constituted of megakaryoblas-
tic cells. (C) Histopathological analysis of the spinal 
cord. Close-up shows a spinal ganglion (inside 
dashed area) surrounded by leukemic cells. (D) His-
topathological analysis of the brain reveals infiltra-
tion of the leptomeninges with leukemic cells. 
Arrow in the main image points to an infiltration  
of leukemic cells also shown in the top left inset; 
arrow in the inset points to a cell in mitosis. Bars: 
(C, left) 5,000 µm; (C [right] and D) 50 µm. (E) MRI 
image of the AMKL7 patient showing abnormal 
signals in several spine areas, suggesting leukemia 
infiltration of the nervous system. Arrow points to 
an abnormal signal.
Table 1. Summary of patient samples xenotransplanted in NSG immunodeficient animals
Patient Age Gender Sample % of blasts Karyotype Engraftment Mean %
AMKL1 6 mo F Fresh 20 46,XX, t(1;22)(p13;q13) [17]/46, idem, ider(11) 
add(11)(p14) t(11;12)(q11;q23) [2]/46,XX [1]
2/4 89.7
AMKL2 21 mo M Frozen 55 55, XY, +6, +9, t(9;11)(p22;q23), +10, +13, +19, +20, +21, 
+22, +22 [18] / 46, XY [2]
1/3 42.7
AMKL3 53 yr M Fresh 70 ND 0/4 NA
AMKL4 15 mo M Frozen 20 51-52 XY, t(2;7)(q23;q21), t(2;11)(p11;p11-12), +4, +6, 
+8, +9, +/ 10, del(13)(q12-q13.14), +21 [17]/ 52-53, 
idem, + 13 [2]/ 46, XY [1]
4/4 60.7
AMKL4R 26 mo M Fresh 75 ND 3/3 32.3
AMKL5 70 yr F Frozen 80 ND 0/4 NA
AMKL6 72 yr M Fresh 87 ND 1/4 16
AMKL7 42 mo M Frozen 80 ND 2/5 66.6
F, female; M, male; NA, not applicable; R, relapse. Age at diagnosis is indicated in months or years. “Mean %” indicates the mean percentage of human cells.
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To assess the recurrence of these fusions, we performed 
RT-PCR analysis on an independent validation cohort of 
22 non-DS pediatric AMKL, 9 DS AMKL, and 8 adult 
AMKL samples (Bourquin et al., 2006). The NUP98-KDM5A 
was found in one non-DS pediatric AMKL. The CBFA2T3-
GLIS2 fusion was detected in seven non-DS pediatric 
AMKL samples (31%) but not in DS AMKL or adult AMKL 
(Figs. 3 B and 5 A), whereas the THRAP3-SH3BP2 and 
SH3BP2-THRAP3 fusions were not detected in the vali-
dation cohort. These fusions genes were mutually exclusive 
with the OTT-MAL fusion. Together, these results indicate 
that the NUP98-KDM5A fusion is a recurrent event in non-
DS AMKL and that a new CBFA2T3-GLIS2 fusion character-
izes the molecular basis of a novel major molecular subgroup 
of non-DS AMKL.
The CBFA2T3 and GLIS2 genes are both localized, in 
inverted orientation, on each arm of chromosome 16 close 
to the telomeres, in 16q24.3 and 16p13.3, respectively. There-
fore, the CBFA2T3-GLIS2 fusion results from a chromo-
somal inversion of chromosome 16 (Fig. 5 B), leading to a 
fusion between exon 11 of CBFA2T3 and exon 3 of GLIS2. 
The GLIS2-CBFA2T3 reciprocal fusion was not detected by 
RNA-seq, suggesting that GLIS2 is not expressed in mega-
karyoblastic cells. RT-PCR analyses to detect expression of 
endogenous CBFA2T3 and GLIS2 in AMKL samples with and 
without the CBFA2T3-GLIS2 fusion confirmed this hypothe-
sis. Indeed, CBFA2T3 was expressed in all AMKL samples, 
blasts for the von Willebrand marker using immunohisto-
chemistry on BM sections (Fig. 1 J, left). Focal infiltrations 
of the liver sinusoids were also observed (Fig. 1 J, right). 
Interestingly, quaternary but not primary recipients of 
AMKL1 cells presented infiltration of spleen and a severe 
infiltration of the kidney (Fig. 1, H and K; and not de-
picted) that was previously described in another mouse 
knockin model of AMKL with Ott-MAL expression (Mercher 
et al., 2009).
In one case (AMKL7), we observed consistent hind leg 
paralysis in all primary, secondary, and tertiary recipients. In 
some animals, a macroscopic tumor was observed near the 
spine, and analysis of the tumor by flow cytometry indicated 
that they were leukemic cells with a megakaryoblastic pheno-
type (Fig. 2, A and B). Detailed histopathological analysis 
of other animals indicated marked infiltration of the spinal 
cord leptomeninges and of the vertebra BM with leukemic 
cells compressing the spinal cord (Fig. 2 C). In addition, the 
cerebral leptomeninges presented multifocal infiltrations with 
proliferating leukemic cells (Fig. 2 D). Interestingly, this 
observation paralleled the clinical record of patient AMKL7 
at advanced stages of the disease as indicated by abnormal 
signals upon magnetic resonance imaging (MRI) analysis 
indicative of spinal cord infiltration within several vertebral 
bodies (Fig. 2 E).
Together, our data indicate that xenotransplantation of 
non-DS primary AMKL patient cells in immunodeficient 
NSG recipient mice enables engraftment of leukemic cells. 
These models recapitulate features of the human disease, in-
cluding low blast counts in the blood, organomegaly, and 
in some instances central nervous system (CNS) infiltration, 
confirming that they can therefore be considered as faithful 
models of human AMKL.
High-throughput RNA-seq identifies novel recurrent  
fusion genes in AMKL
To investigate the molecular basis of non-DS AMKL, we per-
formed high-throughput sequencing of RNA (RNA-seq) 
obtained from FACS-sorted primary recipient leukemic cells. 
Based on the observation that structural alteration may repre-
sent a major type of alteration in AMKL, we searched for fusion 
transcripts that could result from chromosomal translocations, 
inversions, or deletions (Fig. 3 A). To this end, we used the 
TopHat2 and DeFuse software and tuned the program parame-
ters using results from the AMKL1 sample, which was known 
to express the OTT-MAL fusion oncogene. Interestingly, 
fusion genes were detected in all samples (summarized in 
Fig. 3 B), except AMKL6 which was obtained from an adult 
patient. AMKL2 harbored an MLL-AF9 fusion, consistent 
with the detection of a t(9;11)(p22;q23) translocation upon 
subsequent karyotype analysis (Table 1). AMKL4 presented 
a NUP98-KDM5A fusion that was previously identified 
in AML (van Zutven et al., 2006). AMKL7 had three novel 
in-frame fusion transcripts: a CBFA2T3-GLIS2 and a re-
ciprocal fusion, THRAP3-SH3BP2 and SH3BP2-THRAP3 
(Figs. 3 C and 4).
Figure 3. High-throughput RNA-seq identifies novel recurrent 
fusion genes. (A) Scheme of the high-throughput sequencing reads 
supporting the presence of a fusion gene. (B) Summary of the fusion 
genes detected in the different AMKL samples engrafted into immuno-
deficient animals. (C) Sequence of the novel fusion transcripts found in 
AMKL and predicted sequence of the fusion proteins. Arrows indicate 
the fusion point. nd, none detected.
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to GLIS2, the last NHR domain of CBFA2T3, which in-
cludes an MYND (myeloid, nervy, and Deaf-1 domain) 
class of zinc finger domain reported to interact with the 
N-CoR repressor complex, is lost. GLIS2 (GLI-similar 2) 
is a member of the Krüppel-like zinc finger transcription 
factors that are closely related to the GLI family of proteins 
mediating the transcriptional response to the Hedgehog 
pathway activation (Kang et al., 2010; Lichti-Kaiser et al., 
2012). In the CBFA2T3-GLIS2 fusion, all of the GLIS2 
zinc finger domains responsible for interaction with DNA 
whereas GLIS2 expression was only detected in AMKL sam-
ples presenting the CBFA2T3-GLIS2 fusion (Fig. 5 C), in-
dicating that the fusion with CBFA2T3 allows for ectopic 
expression of GLIS2 in megakaryoblastic cells. Accordingly, 
both the CBFA2T3 and the CBFA2T3-GLIS2 proteins could 
be detected in AMKL7 cells (Fig. 5 D).
CBFA2T3, also known as ETO2 or MTG16, is a mem-
ber of the ETO/CBFA2T1/MTG8 family containing three 
members related to the Drosophila melanogaster nervy gene. Of 
note, both CBFA2T1 and CBFA2T3 are fused to RUNX1 
(also known as AML1) in the t(8;21)(q22;q22) translocation 
of AML and t(16;21)(q24;q22) of therapy-related AML, 
respectively (Yamagata et al., 2005). However, the structures 
of the fusions are different, suggesting that the mechanisms of 
transformation are unrelated. The four NHRs (nervy homol-
ogy regions) of CBFA2T3 present amino acid identity of 
90% with those of ETO (Fig. 5 E), and both proteins 
have been found in HDAC (histone deacetylase corepres-
sor) complexes (Davis et al., 2003). As a result of the fusion 
Figure 5. The CBFA2T3-GLIS2 fusion is recurrent in AMKL.  
(A) RT-PCR analysis on a validation cohort of AMKL patients using primers 
located on CBFA2T3 exon 11 and GLIS2 exon 3 (top). Detection of the 
ARNT transcript was used as an RNA quality control. (B) Schematic repre-
sentation of the chromosome 16 chromosomal inversion leading to the 
fusion between CBFA2T3 and GLIS2. Localizations on chromosome and 
exon–intron gene structures are indicated. Red vertical arrows indicate 
the introns targeted by the inversion. Horizontal black arrows indicate 
localization of the primers used for RT-PCR analysis described in C to 
detect the fusion transcript. (C) RT-PCR analysis of CBFA2T3 and GLIS2 
expression in patients with or without the CBFA2T3-GLIS2 fusion. White 
line indicates that intervening lanes have been spliced out. (D) Western 
blot analysis of AMKL7 cells using an anti-CBFA2T3 antibody. AMKL7 cell 
lysates were prepared from fresh cells obtained from tertiary recipients. 
For controls, 293T cells were transfected with empty or CBFA2T3- or  
CBFA2T3-GLIS2–encoding vectors. (E) Schematic representation of the 
CBFA2T3, GLIS2, and CBFA2T3-GLIS2 predicted proteins. Red arrows indi-
cate fusion points on each protein. ZNF, Krüppel-like zinc finger domain.
Figure 4. The THRAP3-SH3BP2 fusion. (A) Schematic representation 
of the fusion between THRAP3 (located on chromosome 1) and SH3BP2 
(located on chromosome 4). Localization on chromosome and exon–
intron gene structure are indicated. Red vertical arrows indicate the tar-
geted introns. Horizontal black arrows indicate localization of the primers 
used for RT-PCR analysis described in B to detect the fusion transcripts. 
(B) RT-PCR analysis on a validation cohort of AMKL patients using the 
primers described in A. Bands appearing in samples 1, 2, and 3 for the 
THRAP-SH3BP2 fusion were not confirmed by direct sequencing and 
therefore represent nonspecific amplification. (C) Schematic representa-
tion of the THRAP3, SH3BP2, THRAP3-SH3BP2, and SH3BP2-THRAP3 pre-
dicted proteins. Red arrows indicate fusion points on each protein.
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and MEIS1 compared with OTT-MAL, CBFA2T3-GLIS2, 
and +21 samples (Fig. 6 G), confirming that most of the 
remaining non-DS AMKL samples have a deregulation of HOX 
genes (Fig. 6 H; Bourquin et al., 2006; Wang et al., 2009).
Surface markers differentially up-regulated in CBFA2T3-
GLIS2 samples represent potentially interesting molecular 
markers for the diagnosis and follow up of AMKL patients 
with this chromosomal alteration. The surface marker 
NCAM1 (CD56) presented a mean differential expression of 
35-fold by microarray and >200-fold by RNA-seq. To vali-
date expression results at the protein level, we compared the 
expression of CD56 between AMKL7 (CBFA2T3-GLIS2) 
and AMKL4 (NUP98-KDM5A) cells. Using flow cytometry, 
we observed that AMKL7 blasts with the CBFA2T3-GLIS2 
fusion are indeed CD41+CD56+ and that CD56 was drasti-
cally more expressed than on NUP98-KDM5A–expressing 
AMKL4 leukemic cells (Fig. 6 I). To assess whether CD56 
could be a direct transcriptional target of the CBFA2T3-
GLIS2 fusion, we performed chromatin immunoprecipita-
tion (ChIP) analysis using a CBFA2T3-specific antibody or a 
nonspecific antibody (IgG) on AMKL7 cells or control K562 
cells. Quantitative PCR was then performed on immuno-
precipitated DNA using several primer pairs located in the 
proximal NCAM1 promoter or in the 3 untranslated region 
(UTR). Specific enrichment at the proximal promoter but 
not the 3 UTR was observed (Fig. 6 J and not depicted) 
with the CBFA2T3 antibody in AMKL7 cells that express 
the CBFA2T3-GLIS2 fusion. In contrast, enrichment was 
not observed in the K562 cell line expressing the endogenous 
CBFA2T3 protein. These data suggest that the CBFA2T3-
GLIS2 fusion protein binds to the proximal promoter of the 
NCAM1 gene.
Together, high-throughput sequencing of RNA from 
AMKL blasts revealed several novel cryptic fusion genes, in-
cluding a CBFA2T3-GLIS2 fusion present in 1/7 non-DS 
AMKL sample in our RNA-seq cohort and 7/22 in a vali-
dation cohort. Samples showing this fusion exhibit a distinct 
molecular signature in global gene expression analysis com-
pared with other non-DS AMKL samples, including up-
regulation of NCAM1 and of several target genes of the 
Hedgehog signaling pathway.
Aurora A kinase (AURKA) inhibitors induce differentiation 
and inhibit proliferation of AMKL patient blasts in vitro  
and in vivo
Finally, we investigated whether these novel models of human 
AMKL are suitable for the screening of novel therapeutic ap-
proaches. Dimethylfasudil (DiMF) was recently identified as a 
small-molecule inhibitor of AMKL cells through a screening 
strategy searching for inducers of megakaryocyte polyploidi-
zation that would inhibit proliferation and engage terminal 
differentiation of megakaryoblastic leukemic cells (Wen 
et al., 2012). Functional analysis indicated that an important 
target of DiMF is AURKA. To assess the efficacy of DiMF and 
AURKA inhibition on the proliferation of human AMKL 
cells with various genetic alterations, we cultured AMKL 
and transactivation (Vasanth et al., 2011) are present (Fig. 5 E). 
These data suggested that this fusion between two transcrip-
tional regulators results in aberrant expression of genes con-
trolled either by CBFA2T3 or GLIS2.
CBFA2T3-GLIS2 AMKL exhibits a distinct  
expression signature
To characterize the molecular consequences of CBFA2T3-
GLIS2 expression, we first analyzed the gene expression 
profile of each AMKL sample by RNA-seq and observed 
that AMKL1 (OTT-MAL fusion) and AMKL7 (CBFA2T3-
GLIS2 fusion) presented specific molecular signatures (Fig. 6 A). 
Principal component analysis of the differentially regulated 
genes allowed homogeneous clustering of CBFA2T3-GLIS2 
samples apart from other samples (Fig. 6 B). To confirm 
these observations, we performed meta-analysis of global 
expression data on the independent cohort in which we 
detected the additional patients with the CBFA2T3-GLIS2 
fusion. We observed that the CBFA2T3-GLIS2 samples 
also presented a molecular signature different from OTT-
MAL and other non-DS AMKL samples (Fig. 6 C and Table S1). 
Therefore, detection of the CBFA2T3-GLIS2 fusion now 
allows the separation of these patients from the OTT-MAL 
patients that were originally in the same consensus cluster 
(Fig. 6, B and C; Bourquin et al., 2006). To identify the most 
robustly deregulated gene signature using both the RNA-seq 
data containing few samples and the microarray data con-
taining more samples, we focused on the intersection be-
tween the RNA-seq and microarray signatures (Fig. 6, 
D and E; and Table S2). For CBFA2T3-GLIS2 samples, all the 
genes of the intersection were up-regulated compared with 
other samples, supporting the idea that CBFA2T3-GLIS2 is a 
transcriptional activator. Among these genes were BMP2 and 
GATA3, two known target genes of the Hedgehog signal-
ing pathway (Craven et al., 2004; Lan and Jiang, 2009), as well 
as IGFBP7, CCND2, NCAM1, and the homeobox HOPX 
(Table S2). Of note, the sample size of the RNA-seq dataset 
and the low overlap between the RNA-seq and microarray 
signature likely reflect the fact that RNA-seq data are based 
on analysis of one sample in each molecular subgroup and the 
corresponding low statistical power. To further investigate the 
alteration of the Hedgehog pathway, we performed gene set 
enrichment analysis (GSEA) on microarray data using a list 
of genes involved in the Hedgehog pathway obtained from 
the KEGG database to compare OTT-MAL and CBFA2T3-
GLIS2 or CBFA2T3-GLIS2 and other non-DS AMKL sam-
ples. In both comparisons, GSEA results showed a significant 
enrichment of this list in CBFA2T3-GLIS2 samples (Fig. 6 F, 
top), with leading edge genes including BMP2, BMP4, WNT3, 
and WNT8B (Fig. 6 F, bottom).
To assess the molecular signature of NUP98-KDM5A, 
we searched the genes differentially expressed in other non-DS 
AMKL samples by comparison with samples with OTT-MAL, 
CBFA2T3-GLIS2, and acquired trisomy 21 (+21). Most of 
the samples in this group, including the NUP98-KDM5A 
sample, presented a strong up-regulation of HOXA9, HOXA10, 
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Figure 6. CBFA2T3-GLIS2 AMKLs exhibit a distinct expression signature. (A) Expression analysis of RNA-seq data showing molecular signature  
of each sample versus all of the other samples. (B) Genes implicated in the signatures indicated in A were used to perform principal component analysis. 
(C) Class comparison of AMKL samples presenting the OTT-MAL fusion, CBFA2T3-GLIS2 fusion, acquired trisomy 21, and other alterations. (D) Venn diagram rep-
resenting common genes between RNA-seq and microarray signatures of AMKL samples presenting CBFA2T3-GLIS2 fusion. (E) Venn diagram represent-
ing common genes between RNA-seq and microarray signatures of AMKL samples presenting OTT-MAL fusion. (F) GSEA using a Hedgehog gene list 
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leukemic blasts purified by FACS from immunodeficient recip-
ients with DiMF and MLN8237, another AURKA inhibitor 
currently being tested in clinical trials for other malignancies. 
We first treated in vitro leukemic cells recovered from AMKL7 
(CBFA2T3-GLIS2) recipient animals with the two drugs and 
monitored their proliferation, differentiation, and ploidy over 
72 h. Both molecules induced a significant enhancement of 
the expression of the maturing megakaryocyte-specific marker 
CD42 (Fig. 7, A and B) paralleled with a significant increase 
in ploidy content (Fig. 7, C and D). This differentiated pheno-
type was associated with an induction of apoptosis detected 
by increased Annexin V (Fig. 7, E and F) and cleaved caspase 3 
(Fig. 7, G and H) and with a drastic inhibition of cell pro-
liferation (Fig. 7 I). Similar results were obtained with other 
AMKL blasts, including AMKL1 (OTT-MAL) and AMKL4 
(NUP98-KDM5A; Fig. 7, J–L).
We then investigated whether treatment with an AURKA 
inhibitor affected disease development in vivo. 2 × 106 
AMKL7 leukemic blasts obtained from tertiary recipients 
were injected per animal into a cohort of quaternary recipi-
ents that were treated with either 15 mg/kg MLN8237 or a 
placebo (Fig. 8 A). 10 d after injection, recipients were ran-
domized to the placebo or MLN8237 groups and treated 
twice daily by oral gavage for 10 d. Although MLN8237 was 
well tolerated by the majority of the mice, 2/7 recipients lost 
>20% of their weight and died soon after the treatment pe-
riod, but importantly, without signs of significant leukemic 
infiltration. The remaining 5/7 MLN8237-treated recipients 
displayed no visible signs of toxicity and presented with 
weight loss <10% on average and could therefore be further 
analyzed. BM sampling 3 d after treatment revealed that 
MLN8237 led to a significant increase in the fraction of 
human CD42+ cells compared with placebo-treated animals 
(Fig. 8 B), which supports an induction of terminal differen-
tiation by MLN8237 in vivo. Placebo-treated recipients pre-
sented a median time to the first signs of hind leg paralysis of 
56 d, whereas MLN8237-treated recipients did not present 
signs of paralysis for up to 80 d (Fig. 8 C). Blood samples col-
lected 30 d after treatment indicated a striking decrease in 
the number of human blasts in MLN8237-treated com-
pared with placebo-treated animals (Fig. 8 D). Placebo-treated 
recipients presented a median survival of 70 d, whereas none 
of the MLN8237 animals succumbed to disease up to 80 d 
(Fig. 8 E). Analysis of the BM from placebo- and MLN8237-
treated animals at day 70 confirmed the low infiltration 
in MLN8237-treated recipients, whereas placebo-treated 
recipients presented massive infiltration (Fig. 8 F). Together, 
these results indicate that treatment of xenograft models of 
human AMKL with MLN8237, a clinically available AURKA 
inhibitor, efficiently inhibits proliferation of AMKL leuke-
mic blasts, reduces disease burden, and increases survival.
DISCUSSION
AMKL is a heterogeneous subtype of AML generally associ-
ated with poor prognosis. Challenges in understanding the 
molecular basis of this disease derive in part from the diffi-
culties in obtaining a sufficient amount of material, which 
together with the lack of experimental model limits the 
development of novel therapeutic strategies. Using a xeno-
transplantation approach with primary human AMKL pa-
tient samples into immunodeficient mice, we have established 
novel models of AMKL recapitulating features of the human 
disease. The leukemic blasts engrafted in immunodeficient 
recipient mice allowed the identification and characteriza-
tion of novel genetic lesions and were relevant models to 
test the efficacy of AURKA inhibitors as a potential thera-
peutic strategy for the treatment of AMKL with various ge-
netic alterations.
Xenotransplantation has been widely used as a strategy to 
propagate human leukemic cells in immunodeficient mice. 
To date however, no specific study of AMKL has been re-
ported. In this study, we have shown that primary AMKL 
patient leukemic cells engraft NSG recipients. Although en-
graftment efficiency was higher with fresh samples, viable 
cells frozen in DMSO could also successfully engraft. We 
observed that the immunophenotype of leukemic cells that 
grow in immunodeficient recipients were heterogeneous, 
especially based on expression of the megakaryocytic marker 
CD41 that could be present on all leukemic cells or only on 
a small fraction. Recipient animals presented several features 
of human disease, including low blast count in the blood, 
massive infiltration of BM with immature megakaryoblastic 
elements, and variable infiltration of the liver and spleen. 
Strikingly, analysis of recipients injected with AMKL cells 
carrying the novel CBFA2T3-GLIS2 fusion oncogene 
showed consistent infiltration of the spinal cord, which was 
also detected by MRI analysis of the patient at late stages of 
the disease. Although, engraftment of additional samples will 
be required to assess whether this phenotype is associated 
with the CBFA2T3-GLIS2 fusion, several observations sug-
gest its relevance for pathology. For example, AMKL, like 
other subtypes of leukemia can present with CNS infiltrations, 
comparing OTT-MAL with CBFA2T3-GLIS2 patients (left) and CBFA2T3-GLIS2 with other non-DS AMKL patients (right). The leading edge genes for each 
comparison are represented in the bottom panels. FDR, false discovery rate. (G) Selected genes from molecular signatures of the different AMKL sub-
groups. Asterisk indicates the patient presenting the NUP98-KDM5A fusion. (H) Schematic representation of all fusion genes found in AMKL samples. 
Hatched squares represent patients with no available material for detection of the novel fusions by bispecific PCR but for which global expression data 
are available. (I) Flow cytometry analysis of CD56 expression on AMKL7 (CBFA2T3-GLIS2) leukemic blasts (right). Comparison of the CD56 expression  
between AMKL4 (NUP98-KDM5A) and AMKL7. (J) ChIP analysis using a CBFA2T3-specific antibody or a nonspecific antibody (IgG) on AMKL7 cells or con-
trol K562 cells. Quantitative PCR was then performed on immunoprecipitated DNA using primer pairs located in the proximal NCAM1 promoter or in the 
3 UTR. Error bars indicate mean ± SEM.
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Figure 7. Aurora kinase inhibitors inhibit 
proliferation of AMKL patient blasts in vitro. 
(A) AMKL7 cells purified from immunodeficient 
recipients were cultured in vitro in the presence 
of DMSO (control), 5 µM DiMF, or 250 nM 
MLN8237 for 72 h. A representative flow cytom-
etry analysis of CD41 and CD42 megakaryocyte–
specific markers is shown. (B) Histogram 
representation of CD41+CD42+ maturing mega-
karyocyte elements shown in A. (C) Representa-
tive ploidy analysis of cells treated as in A.  
(D) Histogram representation of cells with a ploidy  
> 4n shown in C. (E) Representative apoptosis analy-
sis of cells treated as in A. (F) Histogram represen-
tation of apoptotic cells (AnnexinV+7AAD cells) 
shown in E. (G) Representative flow cytometry 
analysis of cleaved caspase 3 in cells treated as in A. 
(H) Histogram representation of cleaved caspase 
3–positive cells shown in G. (B, D, F, and H) Mean 
value ± SEM of duplicate (B and D) or triplicate  
(F and H) experiments is shown. (I) Proliferation 
of AMKL7 leukemic cells upon treatment with 
aurora kinase inhibitors. Mean ± SEM of the 
number of viable cells (trypan blue exclusion, 
duplicate experiments) is shown. (J) Effect of 5 µM 
DiMF and 250 nM MLN8237 treatment on AMKL1 
cells. Flow cytometry analysis of ploidy and 
differentiation after 6 d of in vitro treatment.  
(K) Effect of 5 µM DiMF and 250 nM MLN8237 
treatment on AMKL4 cells. Flow cytometry analy-
sis of ploidy and differentiation after 4 d of  
in vitro treatment. (L) Viable number of AMKL4 cells 
after 4 d of treatment as in K. Means ± SEM of 
duplicate experiments are shown.
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which are generally associated with poor prognosis. In ad-
dition, the CBFA2T3-GLIS2 patients present a homoge-
nous gene expression signature including strong expression 
of CD56, a marker proposed to correlate with CNS infiltra-
tion in acute lymphoblastic leukemia (Ravandi et al., 2002). 
Together, these models may constitute useful tools to fur-
ther investigate the cellular and molecular basis of CNS infil-
tration in leukemia.
Our observations also provided important novel insights 
into the genetic basis of non-DS AMKL. Indeed, high-
throughput sequencing of the RNA obtained from leukemic 
blasts amplified in immunodeficient recipients identified sev-
eral previously undetected fusion genes. First, we character-
ized two patients with a NUP98-KDM5A fusion identical to 
a previously identified chromosomal translocation invisible 
by classical cytogenetics in AML (van Zutven et al., 2006) and 
an MLL-AF9 fusion in another non-DS AMKL patient. 
Although these fusions are rare in non-DS AMKL (8% and 4%, 
respectively in our cohort), MLL and NUP98 alterations were 
previously reported in AMKL (Borkhardt et al., 1995; Allen 
et al., 1998; Morerio et al., 2005; van Zutven et al., 2006; 
Takita et al., 2009; Marques-Salles et al., 2010). Both mutations 
result in deregulation of HOX A cluster genes, respectively, 
through recruitment of the histone H3K79 methyltransferase 
DOT1L by several MLL fusions (Nguyen and Zhang, 2011) 
and through recruitment of the histone acetyltransferase 
CBP/p300 and prevention of differentiation-associated re-
moval of H3K4me3 by NUP98 fusions (Wang et al., 2009). 
Importantly, a larger subgroup of non-DS AMKLs show a 
HOX cluster signature with aberrant expression of HOXA9, 
HOXA10, and MEIS1 (Bourquin et al., 2006), suggesting that 
although individual MLL or NUP98 fusions are rare in 
Figure 8. MLN8237 efficiently reduces disease burden and prolongs survival of a xenograft model of human AMKL expressing the  
CBFA2T3-GLIS2 fusion. (A) Schematic representation of the in vivo drug trial with MLN8237. 2 × 106 AMKL7 cells were injected per recipient. 10 d  
later, two groups of seven recipients were treated either with placebo or 15 mg/kg MLN8237. BM and blood were sampled at the indicated time points  
for analysis. (B) BM cells collected at day 27 were analyzed by flow cytometry. (left) A representative flow cytometry analysis of h–c-KIT, hCD41, and 
hCD42 markers is shown. (right) Scatter plots indicate the result for all recipients. Horizontal lines indicate mean. (C) Representation of the onset of hind 
leg paralysis (Placebo: n = 7, MLN8237: n = 5). (D) Representative analysis (left) and histogram representation (right) of the blood samples collected at 
day 55. (Placebo: n = 7, MLN8237: n = 5). (E) Kaplan-Meier survival curves of placebo-treated (n = 7) and MLN8237-treated (n = 5) animals. (F) BM cells 
collected at day 70 were analyzed by flow cytometry. (left) A representative flow cytometry analysis of cKIT, CD41, and CD42 markers is shown. (right) 
Histogram representation of the results (Placebo: n = 2, MLN8237: n = 5). (D and F) Error bars indicate mean ± SEM.
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fusion will require additional investigation, this fusion was 
associated with treatment-refractory disease in the patient 
analyzed here.
Finally, to experimentally address whether these animal 
models may serve as platforms to assess the relevance of novel 
therapeutic strategies for the treatment of AMKL, we inves-
tigated the effect of DiMF, an inhibitor of AURKA and a 
potent ploidy inducer of various megakaryoblastic leukemia 
cell lines and primary cells on growth of AMKL cells in vivo 
(Wen et al., 2012). Using AMKL patient cells harboring 
various genetic lesions, including OTT-MAL, CBFA2T3-
GLIS2, NUP98-KDM5A, and MLL-AF9 fusions, we show 
that DiMF efficiently induces differentiation and polyploidi-
zation of leukemic blasts and drastically inhibits proliferation 
in vitro for all cases. Similar results were obtained with 
MLN8237, an AURKA inhibitor in clinical trials for other 
tumors. Most importantly, in vivo treatment of mice xeno-
grafted with human AMKL cells bearing the CBFA2T3-
GLIS2 fusion with MLN8237 significantly reduced disease 
burden and prolonged survival of recipient mice. Although 
treatment of additional patient samples is required to pre-
cisely assess the relative sensitivity of each molecular subgroup 
of AMKL to AURKA inhibitors, these observations high-
light that these compounds are promising candidates for the 
treatment of human AMKL independently of their genetic 
lesions. Together, we have demonstrated that modeling 
AMKL using a xenotransplantation approach provides an in-
tegrated platform to gain insights into the molecular genetics 
of AMKL and test novel therapeutic approaches. Our results 
support the idea that CBFA2T3-GLIS2 activates Hedgehog 
pathway genes. Because Hedgehog signaling is not required 
for self-renewal of normal adult hematopoietic progenitors 
(Gao et al., 2009; Hofmann et al., 2009), it will be interesting 
to test whether this molecular subgroup of AMKL is sensitive 
to Hedgehog pathway inhibitors targeting GLI factors.
MATERIALS AND METHODS
Patients. Human AMKL patient blood or BM samples were obtained with 
the informed consent of the patient in accordance with national ethics rules. 
Cells were subjected to Ficoll gradient, immunophenotyped, and used di-
rectly or frozen in FBS supplemented with 10% DMSO.
Animal experiments. 106 AMKL cells were xenotransplanted in toto to 
sublethally irradiated (2–3 Gy) NSG immunodeficient mice (The Jackson 
Laboratory) by i.f. or by i.v. injections. Animals were maintained in pathogen-
free conditions. Engraftment was monitored by blood and BM sampling 
at 6-wk after injection and performed under isoflurane anesthesia. Second-
ary recipients were injected with 0.5 × 106 cells per animal. For histological 
analyses, sample organs were routinely processed into paraffin section and 
stained with hematoxylin and eosin. Immunohistochemistry was per-
formed using the von Willebrand factor antibody (Abcam). For the 
in vivo drug trial, 2 × 106 AMKL7 leukemic blasts obtained from tertiary 
recipients were injected per animal into a cohort of recipients that were 
used for treatment with either 15 mg/kg MLN8237 or a placebo. MLN8237 
was dissolved in 100 mg/ml of an arginine solution. Placebo was comprised 
of the arginine solution alone. 10 d after injection, recipients were randomly 
assigned to the placebo and MLN8237 groups. Recipients were treated twice 
daily by oral gavage for 10 d (5 d of treatment, 2 d off, 5 d of treatment). 
Weight was monitored daily during the treatment period. BM samples were 
AMKL, up-regulation of HOX genes may constitute the 
common mechanism within this subgroup of non-DS AMKL. 
Therefore, additional efforts to characterize other MLL and 
NUP98 fusions are warranted and may lead to identification of 
other genetic alterations resulting in HOX gene activation.
Second, we identified a new recurrent CBFA2T3-GLIS2 
fusion resulting from a cytogenetically cryptic inversion of 
chromosome 16. The CBFA2T3-GLIS2 fusion was detected 
in 31% of pediatric non-DS AMKL, was not detected in adult 
AMKL or DS-AMKL, and was mutually exclusive with the 
OTT-MAL fusion (Gruber et al. 2012. American Association 
for Cancer Research. Abst. 4867). CBFA2T3 is a member 
of the ETO family involved in the NCoR/mSin3a/HDAC 
corepressor complex and is expressed during normal hemato-
poiesis. GLIS2 is a Krüppel-like zinc finger DNA-binding 
transcription factor related to GLI involved in the response to 
the Hedgehog pathway activation and is not expressed in 
megakaryoblastic cells. Of note, GLIS2 inactivating mutations 
have been found in nephronophthisis, an autosomal recessive 
renal disease, and the inactivation of Glis2 in the mouse re-
sults in progressive renal atrophy without reported hemato-
poietic phenotype (Attanasio et al., 2007; Kim et al., 2008). 
Interestingly, patients with the CBFA2T3-GLIS2 fusion pres-
ent a clear expression signature clustering them apart from 
other non-DS AMKL. Among these differentially regulated 
genes are several known targets of the Hedgehog pathway in-
cluding BMP2, BMP4, GATA3, and CCND2 (Craven et al., 
2004; Lan and Jiang, 2009). These observations support the 
hypothesis that the fusion with CBFA2T3 leads to ectopic 
expression of the GLIS2 transcription factor, which in turn 
induces up-regulation of several Hedgehog target genes 
during megakaryopoiesis. Interestingly, Hedgehog pathway 
stimulation was shown to increase megakaryocyte differentia-
tion of CD34+ hematopoietic cells (Martínez et al., 2006), 
and BMP4 was reported to be involved in TPO signaling and 
to play an important role in megakaryopoiesis (Jeanpierre 
et al., 2008), suggesting that aberrant activation of Hedgehog 
target genes by the CBFA2T3-GLIS2 fusion participates in 
the association between this fusion gene and megakaryo-
blastic leukemia. Together with previous studies (Borkhardt 
et al., 1995; Allen et al., 1998; Morerio et al., 2005; Bourquin 
et al., 2006; van Zutven et al., 2006; Takita et al., 2009; 
Marques-Salles et al., 2010), our genetic data indicate that 
non-DS AMKL can be divided into at least four molecular 
subgroups including patients with the OTT-MAL fusion, 
CBFA2T3-GLIS2 fusion, acquired trisomy 21 with a 
GATA1 mutation, and patients presenting a molecular signa-
ture of HOX A gene cluster activation including MLL or 
NUP98 alterations.
These results may also have direct clinical impact. In-
deed, identification and characterization of these novel ge-
netic lesions constitute additional molecular markers for the 
diagnosis and may serve for the detection of the minimal re-
sidual disease during follow up of AMKL patients as described 
previously with the OTT-MAL fusion (Ballerini et al., 2003). 
Of note, although the prognostic value of the CBFA2T3-GLIS2 
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supplemented with protease inhibitors, (b) cells were sonicated, and (c) 
NaCl was added for a final concentration of 150 mM. Western blotting 
was then performed using standard procedures, and the anti-CBFA2T3 
antibody was incubated overnight.
Statistical analysis. Data are depicted as means ± SEM or SD as denoted. 
P-values were calculated using either the Mann–Whitney test or the two-
tailed unpaired Student’s t test (Prism version 4; GraphPad Software). P-values 
for survival curves were calculated using a Log-rank (Mantel-Cox) test 
(Prism version 4).
Online supplemental material. Table S1 shows class comparison be-
tween OTT-MAL, CBFA2T3-GLIS2, and other non-DS AMKLs. Table 
S2 shows the intersection between RNA-seq and microarray expression 
analyses. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20121343/DC1.
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